{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:35:53Z","timestamp":1789461353911,"version":"build-2803163510"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T00:00:00Z","timestamp":1546387200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00198-018-4794-0","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T09:29:51Z","timestamp":1546421391000},"page":"1125-1135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6174-1951","authenticated-orcid":false,"given":"E.","family":"Biver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Calmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Aubry-Rozier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Birkh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. A.","family":"Bischoff-Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. W.","family":"Kressig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Lippuner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Suhm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,2]]},"reference":[{"issue":"43","key":"4794_CR1","first-page":"12","volume":"2017","author":"B Bundesamt f\u00fcr Gesundheit","year":"2017","unstructured":"Bundesamt f\u00fcr Gesundheit B (2017) HIV und Aids in der Schweiz im Jahr 2016. BAG-Bull 2017(43):12\u201319","journal-title":"BAG-Bull"},{"issue":"3","key":"4794_CR2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/QAD.0000000000001335","volume":"31","author":"A Gueler","year":"2017","unstructured":"Gueler A, Moser A, Calmy A, Gunthard HF, Bernasconi E, Furrer H, Fux CA, Battegay M, Cavassini M, Vernazza P, Zwahlen M, Egger M, Swiss Hiv Cohort Study SNC (2017) Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. AIDS 31(3):427\u2013436. \n                    https:\/\/doi.org\/10.1097\/QAD.0000000000001335","journal-title":"AIDS"},{"issue":"3","key":"4794_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/COH.0000000000000269","volume":"11","author":"E Alvarez","year":"2016","unstructured":"Alvarez E, Belloso WH, Boyd MA, Inkaya AC, Hsieh E, Kambugu A, Kaminski G, Martinez E, Stellbrink HJ, Walmsley S, Brown TT, Mallon PW (2016) Which HIV patients should be screened for osteoporosis: an international perspective. Curr Opin HIV AIDS 11(3):268\u2013276. \n                    https:\/\/doi.org\/10.1097\/coh.0000000000000269","journal-title":"Curr Opin HIV AIDS"},{"issue":"6","key":"4794_CR4","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1080\/15284336.2016.1243363","volume":"17","author":"R Bedimo","year":"2016","unstructured":"Bedimo R, Rosenblatt L, Myers J (2016) Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection. HIV Clin Trials 17(6):246\u2013266. \n                    https:\/\/doi.org\/10.1080\/15284336.2016.1243363","journal-title":"HIV Clin Trials"},{"issue":"11","key":"4794_CR5","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/cid\/cir626","volume":"53","author":"B Hasse","year":"2011","unstructured":"Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, Bertisch B, Bernasconi E, Weber R, Swiss HIVCS (2011) Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 53(11):1130\u20131139. \n                    https:\/\/doi.org\/10.1093\/cid\/cir626","journal-title":"Clin Infect Dis"},{"issue":"4","key":"4794_CR6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/joim.12520","volume":"280","author":"J Compston","year":"2016","unstructured":"Compston J (2016) HIV infection and bone disease. J Intern Med 280(4):350\u2013358. \n                    https:\/\/doi.org\/10.1111\/joim.12520","journal-title":"J Intern Med"},{"issue":"1","key":"4794_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1759720X16671927","volume":"9","author":"E Biver","year":"2017","unstructured":"Biver E, Calmy A, Rizzoli R (2017) Bone health in HIV and hepatitis B or C infections. Ther Adv Musculoskelet Dis 9(1):22\u201334. \n                    https:\/\/doi.org\/10.1177\/1759720X16671927","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"4794_CR8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00198-017-4305-8","volume":"29","author":"SSL Goh","year":"2017","unstructured":"Goh SSL, Lai PSM, Tan ATB, Ponnampalavanar S (2017) Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors. Osteoporos Int 29:595\u2013613. \n                    https:\/\/doi.org\/10.1007\/s00198-017-4305-8","journal-title":"Osteoporos Int"},{"issue":"3","key":"4794_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/qad.0000000000001348","volume":"31","author":"M Lachatre","year":"2017","unstructured":"Lachatre M, Pasquet A, Ajana F, Soudan B, Lion G, Bocket L, Cornavin P, Senneville E, Boufassa F, Cheret A (2017) HIV and hypogonadism: a new challenge for young-aged and middle-aged men on effective antiretroviral therapy. AIDS 31(3):451\u2013453. \n                    https:\/\/doi.org\/10.1097\/qad.0000000000001348","journal-title":"AIDS"},{"key":"4794_CR10","doi-asserted-by":"publisher","first-page":"5074923","DOI":"10.1155\/2018\/5074923","volume":"2018","author":"P Echeverr\u00eda","year":"2018","unstructured":"Echeverr\u00eda P, Bonjoch A, Puig J, Estany C, Ornelas A, Clotet B, Negredo E (2018) High prevalence of sarcopenia in HIV-infected individuals. Biomed Res Int 2018:5074923. \n                    https:\/\/doi.org\/10.1155\/2018\/5074923\n                    \n                   eCollection 2018","journal-title":"Biomed Res Int"},{"issue":"11","key":"4794_CR11","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1097\/QAD.0000000000001507","volume":"31","author":"S Bregigeon","year":"2017","unstructured":"Bregigeon S, Galinier A, Zaegel-Faucher O, Cano CE, Obry V, Laroche H, Trijau S, Saout A, Poizot-Martin I (2017) Frailty in HIV infected people: a new risk factor for bone mineral density loss. AIDS 31(11):1573\u20131577. \n                    https:\/\/doi.org\/10.1097\/QAD.0000000000001507","journal-title":"AIDS"},{"issue":"4","key":"4794_CR12","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/cid\/ciw809","volume":"64","author":"H Kovari","year":"2017","unstructured":"Kovari H, Rauch A, Kouyos R, Rougemont M, Cavassini M, Schmid P, Stockle M, Bernasconi E, Weber R, Ledergerber B, Swiss HIVCS (2017) Hepatitis C infection and the risk of non-liver-related morbidity and mortality in HIV-infected persons in the Swiss HIV Cohort Study. Clin Infect Dis 64(4):490\u2013497. \n                    https:\/\/doi.org\/10.1093\/cid\/ciw809","journal-title":"Clin Infect Dis"},{"key":"4794_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.maturitas.2016.10.015","volume":"95","author":"F Finnerty","year":"2017","unstructured":"Finnerty F, Walker-Bone K, Tariq S (2017) Osteoporosis in postmenopausal women living with HIV. Maturitas 95:50\u201354. \n                    https:\/\/doi.org\/10.1016\/j.maturitas.2016.10.015","journal-title":"Maturitas"},{"issue":"5","key":"4794_CR14","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1093\/jac\/dkx011","volume":"72","author":"L Slama","year":"2017","unstructured":"Slama L, Reddy S, Phair J, Palella FJ Jr, Brown TT, ACSg M (2017) Changes in bone turnover markers with HIV seroconversion and ART initiation. J Antimicrob Chemother 72(5):1456\u20131461. \n                    https:\/\/doi.org\/10.1093\/jac\/dkx011","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"4794_CR15","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1097\/QAD.0000000000000320","volume":"28","author":"CO Hileman","year":"2014","unstructured":"Hileman CO, Labbato DE, Storer NJ, Tangpricha V, McComsey GA (2014) Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study. AIDS 28(12):1759\u20131767. \n                    https:\/\/doi.org\/10.1097\/QAD.0000000000000320","journal-title":"AIDS"},{"issue":"9","key":"4794_CR16","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/jbmr.3183","volume":"32","author":"JF Hoy","year":"2017","unstructured":"Hoy JF, Grund B, Roediger M, Schwartz AV, Shepherd J, Avihingsanon A, Badal-Faesen S, de Wit S, Jacoby S, La Rosa A, Pujari S, Schechter M, White D, Engen NW, Ensrud K, Aagaard PD, Carr A, Group ISBMDS (2017) Immediate initiation of antiretroviral therapy for HIV infection accelerates bone loss relative to deferring therapy: findings from the START Bone Mineral Density Substudy, a randomized trial. J Bone Miner Res 32(9):1945\u20131955. \n                    https:\/\/doi.org\/10.1002\/jbmr.3183","journal-title":"J Bone Miner Res"},{"issue":"2","key":"4794_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s001980200001","volume":"13","author":"L Warming","year":"2002","unstructured":"Warming L, Hassager C, Christiansen C (2002) Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int 13(2):105\u2013112. \n                    https:\/\/doi.org\/10.1007\/s001980200001","journal-title":"Osteoporos Int"},{"issue":"6","key":"4794_CR18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11904-016-0336-6","volume":"13","author":"MN Weitzmann","year":"2016","unstructured":"Weitzmann MN, Ofotokun I, Titanji K, Sharma A, Yin MT (2016) Bone loss among women living with HIV. Curr HIV\/AIDS Rep 13(6):367\u2013373. \n                    https:\/\/doi.org\/10.1007\/s11904-016-0336-6","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"1","key":"4794_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S2213-8587(13)70181-5","volume":"3","author":"MJ Bolland","year":"2015","unstructured":"Bolland MJ, Grey A, Reid IR (2015) Skeletal health in adults with HIV infection. Lancet Diabetes Endocrinol 3(1):63\u201374. \n                    https:\/\/doi.org\/10.1016\/S2213-8587(13)70181-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"4794_CR20","doi-asserted-by":"publisher","first-page":"e23688","DOI":"10.1371\/journal.pone.0023688","volume":"6","author":"AY Liu","year":"2011","unstructured":"Liu AY, Vittinghoff E, Sellmeyer DE, Irvin R, Mulligan K, Mayer K, Thompson M, Grant R, Pathak S, O\u2019Hara B, Gvetadze R, Chillag K, Grohskopf L, Buchbinder SP (2011) Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One 6(8):e23688. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0023688","journal-title":"PLoS One"},{"issue":"4","key":"4794_CR21","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1093\/cid\/civ324","volume":"61","author":"K Mulligan","year":"2015","unstructured":"Mulligan K, Glidden DV, Anderson PL, Liu A, McMahan V, Gonzales P, Ramirez-Cardich ME, Namwongprom S, Chodacki P, de Mendonca LM, Wang F, Lama JR, Chariyalertsak S, Guanira JV, Buchbinder S, Bekker LG, Schechter M, Veloso VG, Grant RM (2015) Effects of emtricitabine\/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 61(4):572\u2013580. \n                    https:\/\/doi.org\/10.1093\/cid\/civ324","journal-title":"Clin Infect Dis"},{"issue":"7","key":"4794_CR22","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1097\/QAD.0b013e328328f789","volume":"23","author":"C Duvivier","year":"2009","unstructured":"Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, Katlama C, Costagliola D (2009) Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 23(7):817\u2013824. \n                    https:\/\/doi.org\/10.1097\/QAD.0b013e328328f789","journal-title":"AIDS"},{"issue":"12","key":"4794_CR23","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1093\/infdis\/jir188","volume":"203","author":"GA McComsey","year":"2011","unstructured":"McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, Myers L, Melbourne K, Ha B, Sax PE (2011) Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 203(12):1791\u20131801. \n                    https:\/\/doi.org\/10.1093\/infdis\/jir188","journal-title":"J Infect Dis"},{"issue":"3","key":"4794_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/COH.0000000000000260","volume":"11","author":"CA Moran","year":"2016","unstructured":"Moran CA, Weitzmann MN, Ofotokun I (2016) The protease inhibitors and HIV-associated bone loss. Curr Opin HIV AIDS 11(3):333\u2013342. \n                    https:\/\/doi.org\/10.1097\/COH.0000000000000260","journal-title":"Curr Opin HIV AIDS"},{"issue":"8","key":"4794_CR25","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/infdis\/jiv194","volume":"212","author":"TT Brown","year":"2015","unstructured":"Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T, Yang O, Dube MP, Murphy RL, Stein JH, McComsey GA (2015) Changes in bone mineral density after initiation of antiretroviral treatment with tenofovir disoproxil fumarate\/emtricitabine plus atazanavir\/ritonavir, darunavir\/ritonavir, or raltegravir. J Infect Dis 212(8):1241\u20131249. \n                    https:\/\/doi.org\/10.1093\/infdis\/jiv194","journal-title":"J Infect Dis"},{"issue":"10","key":"4794_CR26","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s001980200108","volume":"13","author":"TP Staa van","year":"2002","unstructured":"van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13(10):777\u2013787. \n                    https:\/\/doi.org\/10.1007\/s001980200108","journal-title":"Osteoporos Int"},{"issue":"5","key":"4794_CR27","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/QAD.0000000000001372","volume":"31","author":"W Tinago","year":"2017","unstructured":"Tinago W, Cotter AG, Sabin CA, Macken A, Kavanagh E, Brady JJ, McCarthy G, Compston J, Mallon PW (2017) Predictors of longitudinal change in bone mineral density in a cohort of HIV-positive and negative patients. AIDS 31(5):643\u2013652. \n                    https:\/\/doi.org\/10.1097\/qad.0000000000001372","journal-title":"AIDS"},{"issue":"16","key":"4794_CR28","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1097\/QAD.0000000000000445","volume":"28","author":"E Biver","year":"2014","unstructured":"Biver E, Calmy A, Delhumeau C, Durosier C, Zawadynski S, Rizzoli R (2014) Microstructural alterations of trabecular and cortical bone in long-term HIV-infected elderly men on successful antiretroviral therapy. AIDS 28(16):2417\u20132427","journal-title":"AIDS"},{"issue":"12","key":"4794_CR29","doi-asserted-by":"publisher","first-page":"815","DOI":"10.7326\/M14-1409","volume":"162","author":"ET Overton","year":"2015","unstructured":"Overton ET, Chan ES, Brown TT, Tebas P, McComsey GA, Melbourne KM, Napoli A, Hardin WR, Ribaudo HJ, Yin MT (2015) Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: a randomized trial. Ann Intern Med 162(12):815\u2013824. \n                    https:\/\/doi.org\/10.7326\/M14-1409","journal-title":"Ann Intern Med"},{"issue":"2","key":"4794_CR30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/cid\/cix753","volume":"66","author":"PL Havens","year":"2018","unstructured":"Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Harris DR, Price G, Baker A, Meyer WA 3rd, Wilson CM, Hazra R, Kapogiannis BG, Mulligan K (2018) Vitamin D3 supplementation increases spine bone mineral density in adolescents and young adults with human immunodeficiency virus infection being treated with tenofovir disoproxil fumarate: a randomized, placebo-controlled trial. Clin Infect Dis 66(2):220\u2013228. \n                    https:\/\/doi.org\/10.1093\/cid\/cix753","journal-title":"Clin Infect Dis"},{"issue":"5","key":"4794_CR31","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/cid\/ciw331","volume":"63","author":"I Ofotokun","year":"2016","unstructured":"Ofotokun I, Titanji K, Lahiri CD, Vunnava A, Foster A, Sanford SE, Sheth AN, Lennox JL, Knezevic A, Ward L, Easley KA, Powers P, Weitzmann MN (2016) A single-dose zoledronic acid infusion prevents antiretroviral therapy-induced bone loss in treatment-naive HIV-infected patients: a phase IIb trial. Clin Infect Dis 63(5):663\u2013671. \n                    https:\/\/doi.org\/10.1093\/cid\/ciw331","journal-title":"Clin Infect Dis"},{"issue":"10","key":"4794_CR32","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1086\/644769","volume":"49","author":"A Martin","year":"2009","unstructured":"Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, Carr A (2009) Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 49(10):1591\u20131601. \n                    https:\/\/doi.org\/10.1086\/644769","journal-title":"Clin Infect Dis"},{"issue":"4","key":"4794_CR33","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/qad.0000000000001725","volume":"32","author":"GA McComsey","year":"2018","unstructured":"McComsey GA, Lupo S, Parks D, Poggio MC, De Wet J, Kahl LP, Angelis K, Wynne B, Vandermeulen K, Gartland M, Cupo M, Aboud M (2018) Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health. AIDS 32(4):477\u2013485. \n                    https:\/\/doi.org\/10.1097\/qad.0000000000001725","journal-title":"AIDS"},{"issue":"1","key":"4794_CR34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","volume":"16","author":"A Mills","year":"2016","unstructured":"Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, Elion R, Cavassini M, Madruga JV, Brunetta J, Shamblaw D, DeJesus E, Orkin C, Wohl DA, Brar I, Stephens JL, Girard PM, Huhn G, Plummer A, Liu YP, Cheng AK, McCallister S, team G-U (2016) Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis 16(1):43\u201352. \n                    https:\/\/doi.org\/10.1016\/S1473-3099(15)00348-5","journal-title":"Lancet Infect Dis"},{"issue":"9987","key":"4794_CR35","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","volume":"385","author":"PE Sax","year":"2015","unstructured":"Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S (2015) Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 385(9987):2606\u20132615. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(15)60616-x","journal-title":"Lancet"},{"issue":"4","key":"4794_CR36","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/COH.0000000000000379","volume":"12","author":"D Gotham","year":"2017","unstructured":"Gotham D, Hill A, Pozniak AL (2017) Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide. Curr Opin HIV AIDS 12(4):324\u2013333. \n                    https:\/\/doi.org\/10.1097\/COH.0000000000000379","journal-title":"Curr Opin HIV AIDS"},{"issue":"14","key":"4794_CR37","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1097\/QAD.0000000000001911","volume":"32","author":"JF Hoy","year":"2018","unstructured":"Hoy JF, Richardson R, Ebeling PR, Rojas J, Pocock N, Kerr SJ, Martinez E, Carr A, ZEST Study Investigators (2018) Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV. AIDSAIDS 32(14):1967\u20131975. \n                    https:\/\/doi.org\/10.1097\/QAD.0000000000001911","journal-title":"AIDSAIDS"},{"issue":"31","key":"4794_CR38","doi-asserted-by":"publisher","first-page":"13848","DOI":"10.1073\/pnas.1003020107","volume":"107","author":"T Vikulina","year":"2010","unstructured":"Vikulina T, Fan X, Yamaguchi M, Roser-Page S, Zayzafoon M, Guidot DM, Ofotokun I, Weitzmann MN (2010) Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A 107(31):13848\u201313853. \n                    https:\/\/doi.org\/10.1073\/pnas.1003020107","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"4794_CR39","doi-asserted-by":"publisher","first-page":"e1004497","DOI":"10.1371\/journal.ppat.1004497","volume":"10","author":"K Titanji","year":"2014","unstructured":"Titanji K, Vunnava A, Sheth AN, Delille C, Lennox JL, Sanford SE, Foster A, Knezevic A, Easley KA, Weitzmann MN, Ofotokun I (2014) Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection. PLoS Pathog 10(10):e1004497. \n                    https:\/\/doi.org\/10.1371\/journal.ppat.1004497","journal-title":"PLoS Pathog"},{"issue":"1","key":"4794_CR40","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s40506-017-0109-9","volume":"9","author":"CA Moran","year":"2017","unstructured":"Moran CA, Weitzmann MN, Ofotokun I (2017) Bone loss in HIV infection. Curr Treat Options Infect Dis 9(1):52\u201367. \n                    https:\/\/doi.org\/10.1007\/s40506-017-0109-9","journal-title":"Curr Treat Options Infect Dis"},{"issue":"3","key":"4794_CR41","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/QAD.0000000000000918","volume":"30","author":"I Ofotokun","year":"2016","unstructured":"Ofotokun I, Titanji K, Vunnava A, Roser-Page S, Vikulina T, Villinger F, Rogers K, Sheth AN, Lahiri CD, Lennox JL, Weitzmann MN (2016) Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection. AIDS 30(3):405\u2013414. \n                    https:\/\/doi.org\/10.1097\/QAD.0000000000000918","journal-title":"AIDS"},{"key":"4794_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9282","volume":"6","author":"I Ofotokun","year":"2015","unstructured":"Ofotokun I, Titanji K, Vikulina T, Roser-Page S, Yamaguchi M, Zayzafoon M, Williams IR, Weitzmann MN (2015) Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss. Nat Commun 6:8282. \n                    https:\/\/doi.org\/10.1038\/ncomms9282","journal-title":"Nat Commun"},{"key":"4794_CR43","unstructured":"Rockstroh JOC, Yazdanpanah Y, Di Perri G, Sax PE, Arribas JR, Brinkman K, Wohl DA, Cheng A, Zhong L, McCallister S, Das M (2017) Switching from TDF to TAF improves bone and renal safety independent of age, sex, race, or 3rd agent: results from pooled analysis (N=2816) of virologically suppressed HIV-1 infected adults. Abstract MOPEB0289, 9th IAS Conference on HIV Science, Paris. Available at \n                    http:\/\/www.ias2017.org\/Portals\/1\/Files\/IAS2017_LO.compressed.pdf?ver=2017-07-27-211231-197"},{"issue":"4","key":"4794_CR44","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/QAI.0000000000000986","volume":"72","author":"JL Casado","year":"2016","unstructured":"Casado JL, Del Rey JM, Banon S, Santiuste C, Rodriguez M, Moreno A, Perez-Elias MJ, Liano F, Moreno S (2016) Changes in kidney function and in the rate of tubular dysfunction after tenofovir withdrawal or continuation in HIV-infected patients. J Acquir Immune Defic Syndr 72(4):416\u2013422. \n                    https:\/\/doi.org\/10.1097\/QAI.0000000000000986","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"4794_CR45","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/QAD.0000000000000901","volume":"30","author":"JL Casado","year":"2016","unstructured":"Casado JL, Banon S, Santiuste C, Serna J, Guzman P, Tenorio M, Liano F, del Rey JM (2016) Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir. AIDS 30(2):231\u2013239. \n                    https:\/\/doi.org\/10.1097\/QAD.0000000000000901","journal-title":"AIDS"},{"issue":"9","key":"4794_CR46","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1097\/QAD.0000000000001067","volume":"30","author":"JL Casado","year":"2016","unstructured":"Casado JL, Santiuste C, Vazquez M, Banon S, Rosillo M, Gomez A, Perez-Elias MJ, Caballero C, Rey JM, Moreno S (2016) Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients. AIDS 30(9):1423\u20131431. \n                    https:\/\/doi.org\/10.1097\/QAD.0000000000001067","journal-title":"AIDS"},{"issue":"7","key":"4794_CR47","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1093\/jac\/dkx076","volume":"72","author":"SK Gupta","year":"2017","unstructured":"Gupta SK, Yeh E, Kitch DW, Brown TT, Venuto CS, Morse GD, Ha B, Melbourne K, McComsey GA (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72(7):2042\u20132048. \n                    https:\/\/doi.org\/10.1093\/jac\/dkx076","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"4794_CR48","doi-asserted-by":"publisher","first-page":"e0175517","DOI":"10.1371\/journal.pone.0175517","volume":"12","author":"M Manion","year":"2017","unstructured":"Manion M, Hullsiek KH, Wilson EMP, Rhame F, Kojic E, Gibson D, Hammer J, Patel P, Brooks JT, Baker JV, Sereti I, Study to Understand the Natural History of HIVAitEoEATI (2017) Vitamin D deficiency is associated with IL-6 levels and monocyte activation in HIV-infected persons. PLoS One 12(5):e0175517. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0175517","journal-title":"PLoS One"},{"issue":"4","key":"4794_CR49","doi-asserted-by":"publisher","first-page":"e95164","DOI":"10.1371\/journal.pone.0095164","volume":"9","author":"FP Havers","year":"2014","unstructured":"Havers FP, Detrick B, Cardoso SW, Berendes S, Lama JR, Sugandhavesa P, Mwelase NH, Campbell TB, Gupta A, Actg AP, Teams NS (2014) Change in vitamin d levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings. PLoS One 9(4):e95164. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0095164","journal-title":"PLoS One"},{"issue":"2","key":"4794_CR50","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3851\/IMP2721","volume":"19","author":"DA Wohl","year":"2014","unstructured":"Wohl DA, Orkin C, Doroana M, Pilotto JH, Sungkanuparph S, Yeni P, Vanveggel S, Deckx H, Boven K (2014) Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a phase III trial (ECHO). Antivir Ther 19(2):191\u2013200. \n                    https:\/\/doi.org\/10.3851\/IMP2721","journal-title":"Antivir Ther"},{"issue":"3","key":"4794_CR51","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/COH.0000000000000249","volume":"11","author":"J Hoy","year":"2016","unstructured":"Hoy J, Young B (2016) Do people with HIV infection have a higher risk of fracture compared with those without HIV infection? Curr Opin HIV AIDS 11(3):301\u2013305. \n                    https:\/\/doi.org\/10.1097\/COH.0000000000000249","journal-title":"Curr Opin HIV AIDS"},{"issue":"17","key":"4794_CR52","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1097\/QAD.0b013e32833f6294","volume":"24","author":"MT Yin","year":"2010","unstructured":"Yin MT, Shi Q, Hoover DR, Anastos K, Sharma A, Young M, Levine A, Cohen MH, Shane E, Golub ET, Tien PC (2010) Fracture incidence in HIV-infected women: results from the Women\u2019s Interagency HIV Study. AIDS 24(17):2679\u20132686. \n                    https:\/\/doi.org\/10.1097\/QAD.0b013e32833f6294","journal-title":"AIDS"},{"issue":"10","key":"4794_CR53","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/QAD.0000000000001493","volume":"31","author":"A Gonciulea","year":"2017","unstructured":"Gonciulea A, Wang R, Althoff KN, Palella FJ, Lake J, Kingsley LA, Brown TT (2017) An increased rate of fracture occurs a decade earlier in HIV+ compared with HIV- men. AIDS 31(10):1435\u20131443. \n                    https:\/\/doi.org\/10.1097\/QAD.0000000000001493","journal-title":"AIDS"},{"issue":"8","key":"4794_CR54","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1093\/cid\/civ010","volume":"60","author":"TT Brown","year":"2015","unstructured":"Brown TT, Hoy J, Borderi M, Guaraldi G, Renjifo B, Vescini F, Yin MT, Powderly WG (2015) Recommendations for evaluation and management of bone disease in HIV. Clin Infect Dis 60(8):1242\u20131251. \n                    https:\/\/doi.org\/10.1093\/cid\/civ010","journal-title":"Clin Infect Dis"},{"issue":"5","key":"4794_CR55","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/QAI.0000000000000998","volume":"72","author":"MT Yin","year":"2016","unstructured":"Yin MT, Shiau S, Rimland D, Gibert CL, Bedimo RJ, Rodriguez-Barradas MC, Harwood K, Aschheim J, Justice AC, Womack JA (2016) Fracture prediction with modified-FRAX in older HIV-infected and uninfected men. J Acquir Immune Defic Syndr 72(5):513\u2013520. \n                    https:\/\/doi.org\/10.1097\/QAI.0000000000000998","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"4794_CR56","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/jbmr.2734","volume":"31","author":"EV McCloskey","year":"2016","unstructured":"McCloskey EV, Oden A, Harvey NC, Leslie WD, Hans D, Johansson H, Barkmann R, Boutroy S, Brown J, Chapurlat R, Elders PJ, Fujita Y, Gluer CC, Goltzman D, Iki M, Karlsson M, Kindmark A, Kotowicz M, Kurumatani N, Kwok T, Lamy O, Leung J, Lippuner K, Ljunggren O, Lorentzon M, Mellstrom D, Merlijn T, Oei L, Ohlsson C, Pasco JA, Rivadeneira F, Rosengren B, Sornay-Rendu E, Szulc P, Tamaki J, Kanis JA (2016) A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res 31(5):940\u2013948. \n                    https:\/\/doi.org\/10.1002\/jbmr.2734","journal-title":"J Bone Miner Res"},{"issue":"1","key":"4794_CR57","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00774-017-0819-6","volume":"36","author":"L Ciullini","year":"2018","unstructured":"Ciullini L, Pennica A, Argento G, Novarini D, Teti E, Pugliese G, Aceti A, Conti FG (2018) Trabecular bone score (TBS) is associated with sub-clinical vertebral fractures in HIV-infected patients. J Bone Miner Metab 36(1):111\u2013118. \n                    https:\/\/doi.org\/10.1007\/s00774-017-0819-6","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"4794_CR58","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/15284336.2016.1266074","volume":"18","author":"DH Tan","year":"2017","unstructured":"Tan DH, Raboud J, Szadkowski L, Szabo E, Hu H, Wong Q, Cheung AM, Walmsley SL (2017) Novel imaging modalities for the comparison of bone microarchitecture among HIV+ patients with and without fractures: a pilot study. HIV Clin Trials 18(1):28\u201338. \n                    https:\/\/doi.org\/10.1080\/15284336.2016.1266074","journal-title":"HIV Clin Trials"},{"key":"4794_CR59","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1093\/cid\/cix1011","volume":"66","author":"RJ Bedimo","year":"2017","unstructured":"Bedimo RJ, Adams-Huet B, Poindexter J, Brown G, Farukhi I, Castanon R, Turner D, Moore T, Tebas P, Maalouf NM (2017) The differential effects of HIV and HCV on bone micro-architecture and fracture risk. Clin Infect Dis 66:1442\u20131447. \n                    https:\/\/doi.org\/10.1093\/cid\/cix1011","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4794_CR60","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/QAI.0000000000001396","volume":"75","author":"R Guerri-Fernandez","year":"2017","unstructured":"Guerri-Fernandez R, Molina-Morant D, Villar-Garcia J, Herrera S, Gonzalez-Mena A, Guelar A, Trenchs-Rodriguez M, Diez-Perez A, Knobel H (2017) Bone density, microarchitecture, and tissue quality after long-term treatment with tenofovir\/emtricitabine or abacavir\/lamivudine. J Acquir Immune Defic Syndr 75(3):322\u2013327. \n                    https:\/\/doi.org\/10.1097\/qai.0000000000001396","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4794_CR61","unstructured":"Recommendations of the Swiss Association against Osteoporosis (SVGO\/ASCO) (2015) Prevention, diagnostic and treatment of osteoporosis. Available from: \n                    http:\/\/www.svgo.ch\/content\/documents\/2015\/SVGO%20Empfehlungen%202015.pdf"},{"key":"4794_CR62","unstructured":"Bischoff Ferrari HA, Burckhardt P, QuackLoetscher K, Gerber B, I\u2019Allemand D, Laimbacher J, Bachmannan M, Rizzoli R (2012) Vitamin D deficiency: evidence, safety, and recommendations for the Swiss population. Report written by a group of experts on behalf of the Federal Commission for Nutrition. Approved by the Federal Commission for Nutrition on November 3, 2011 \n                    http:\/\/www.bagadminch\/themen\/ernaehrung_bewegung\/05207\/13246\/indexhtml?lang=de"},{"issue":"3","key":"4794_CR63","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00198-009-0975-1","volume":"21","author":"K Lippuner","year":"2010","unstructured":"Lippuner K, Johansson H, Kanis JA, Rizzoli R (2010) FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 21(3):381\u2013389. \n                    https:\/\/doi.org\/10.1007\/s00198-009-0975-1","journal-title":"Osteoporos Int"},{"issue":"3","key":"4794_CR64","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/COH.0000000000000271","volume":"11","author":"E Negredo","year":"2016","unstructured":"Negredo E, Warriner AH (2016) Pharmacologic approaches to the prevention and management of low bone mineral density in HIV-infected patients. Curr Opin HIV AIDS 11(3):351\u2013357. \n                    https:\/\/doi.org\/10.1097\/COH.0000000000000271","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"4794_CR65","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/hiv.12291","volume":"17","author":"J Natsag","year":"2016","unstructured":"Natsag J, Kendall MA, Sellmeyer DE, McComsey GA, Brown TT (2016) Vitamin D, osteoprotegerin\/receptor activator of nuclear factor-kappaB ligand (OPG\/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density. HIV Med 17(3):196\u2013205. \n                    https:\/\/doi.org\/10.1111\/hiv.12291","journal-title":"HIV Med"},{"issue":"2","key":"4794_CR66","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/QAD.0000000000000529","volume":"29","author":"AL Wheeler","year":"2015","unstructured":"Wheeler AL, Tien PC, Grunfeld C, Schafer AL (2015) Teriparatide treatment of osteoporosis in an HIV-infected man: a case report and literature review. AIDS 29(2):245\u2013246. \n                    https:\/\/doi.org\/10.1097\/QAD.0000000000000529","journal-title":"AIDS"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-018-4794-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-018-4794-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-018-4794-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T19:15:00Z","timestamp":1577906100000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-018-4794-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,2]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["4794"],"URL":"https:\/\/doi.org\/10.1007\/s00198-018-4794-0","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,2]]},"assertion":[{"value":"22 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Alexandra Calmy has received travel grants from Gilead and unrestricted educational grants from Gilead, ViiV, MSD, and AbbVie. Emmanuel Biver, B\u00e9reng\u00e8re Aubry-Rozier, Martin Birkh\u00e4user, Heike A. Bischoff-Ferrari, Serge Ferrari, Diana Frey, Reto W. Kressig, Olivier Lamy, Kurt Lippuner, Norbert Suhm, and Christian Meier declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}